Quick Answer
Aptevo Therapeutics Inc. reported Total Revenue of $3.11 million for fiscal year 2022.
Aptevo Therapeutics Inc. Total Revenue — Annual History
| Fiscal Year | Total Revenue | YoY Change |
|---|---|---|
| 2022 | $3.11M | -74.7% |
| 2021 | $12.29M | +185.3% |
| 2020 | $4.31M | -86.7% |
| 2019 | $32.42M | +40.6% |
| 2018 | $23.07M | +57.4% |
| 2017 | $14.66M | +46.8% |
| 2016 | $9.98M | -70.3% |
| 2015 | $33.60M | — |
Quarterly Total Revenue
| Quarter Ending | Total Revenue | YoY | QoQ |
|---|---|---|---|
| March 31, 2022 | $3.11M | +28.6% | +0.6% |
| September 30, 2021 | $3.10M | +111.6% | -0.5% |
| June 30, 2021 | $3.11M | +557.5% | +28.5% |
| March 31, 2021 | $2.42M | — | +65.5% |
| September 30, 2020 | $1.46M | -83.8% | +209.3% |
| June 30, 2020 | $473.0K | -93.6% | -94.8% |
| September 30, 2019 | $9.01M | +54.7% | +22.4% |
| June 30, 2019 | $7.36M | +7.8% | +4.8% |
- Aptevo Therapeutics Inc. showed a decrease of -74.7% in Total Revenue compared to the prior fiscal year.
- Over the 2015–2022 period, Aptevo Therapeutics Inc.’s total revenue has declined by 90.7% (from $33.60 million to $3.11 million).
- The most recent figure is from Aptevo Therapeutics Inc.’s fiscal year 2023 report (Form 10-K), filed with the SEC on March 5, 2024.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: